TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03358017
Drug: Atorvastatin 80mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg /die os for 6 months
Study: NCT02160223
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
Study: NCT02160223
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
Study: NCT05110118
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single intravenous injection
Study: NCT04124302
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
Study: NCT04124302
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
Study: NCT01937832
Drug: Faropenem
Normalized name: Faropenem
DrugBank: Faropenem (DB12190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: Injection dosage:1200 mg frequency: Three times a day
Study: NCT01937832
Drug: Ertapenem
Normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dosage form: Injection dosage:1000 mg frequency: once a day
Study: NCT04124302
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Study: NCT00072982
Drug: fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
Study: NCT01148979
Drug: Lisdexamfetamine Dimesylate (Vyvanse)
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
Study: NCT00072982
Drug: combination fish oil and borage seed oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
Study: NCT01132027
Drug: Tacrolimus Capsules
Normalized name: Tacrolimus Capsules
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
Study: NCT01748162
Drug: Fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
Study: NCT00777153
Drug: Cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day, oral, until progression
Study: NCT00777153
Drug: Cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day, oral, until progression
Study: NCT00777153
Drug: Lomustine Chemotherapy
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 110 mg/m2 / Q6W, oral, until progression
Study: NCT00777153
Drug: Placebo Cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, until progression
Study: NCT03653507
Drug: zolbetuximab
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolbetuximab were administered as a minimum 2-hour IV infusion.
Study: NCT03653507
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin were administered as a 2-hour IV infusion.
Study: NCT00895206
Drug: individual adapted immunosuppression
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: individual adapted immunosuppression
Study: NCT00895206
Drug: golden standard therapy
Normalized name: GOLDEN SEAL
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: golden standard therapy
Study: NCT01516541
Drug: dalcetrapib
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg orally daily
Study: NCT00554216
Drug: VI-0521
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg phentermine/23 mg topiramate
Study: NCT00554216
Drug: VI-0521
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg phentermine/92 mg topiramate
Study: NCT00554216
Drug: Placebo matched phentermine/topiramate
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo matched phentermine/topiramate
Study: NCT04463459
Drug: Vitamin C, Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin C (500mg) twice daily and Vitamin E (400mg) once daily
Study: NCT01933568
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combined CFRT and SABR with concurrent cisplatin
Study: NCT00990704
Drug: paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration 3 times a week immediately before completion of dialysis
Study: NCT00990704
Drug: maxacalcitol
Normalized name: Maxacalcitol
DrugBank: Maxacalcitol (DB06272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration 3 times a week immediately before completion of dialysis
Study: NCT03851562
Drug: Alprostadil 20 micrograms
Normalized name: alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of PGE1 (Days 0, +1 and +2)
Study: NCT01819012
Drug: Isoflurane 1.0 MAC
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 min-inhalation of each concentration of isoflurane, 1.0 MAC
Study: NCT01819012
Drug: Isoflurane 1.5 MAC
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 min-inhalation of each concentration of isoflurane, 1.5 MAC
Study: NCT01819012
Drug: Isoflurane 2.0 MAC
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 min-inhalation of each concentration of isoflurane, 2.0 MAC
Study: NCT00913952
Drug: Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions
Normalized name: clomipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913952
Drug: Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
Normalized name: clomipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00913952
Drug: Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions
Normalized name: clomipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00283621
Drug: Aranesp (darbepoetin alfa)
Normalized name: darbepoetin alfa Injection [Aranesp]
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00283621
Drug: Neulasta (pegfilgrastim)
Normalized name: pegfilgrastim Injection [Neulasta]
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00283621
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00283621
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04675008
Drug: Dacomitinib
Normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
Study: NCT01071798
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As prescribed by physician
Study: NCT03016000
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
Study: NCT00482066
Drug: Abatacept (Orencia)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients\>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v.
Study: NCT01732718
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet by mouth daily for 6 weeks
Study: NCT02824042
Drug: Anetumab ravtansine (BAY94-9343)
Normalized name: mirvetuximab soravtansine
DrugBank: Anetumab ravtansine (DB14809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
Study: NCT02824042
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
Study: NCT03773796
Drug: Nabilone 0.25 mg
Normalized name: nabilone 0.25 MG
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
Study: NCT01467518
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
Study: NCT01467518
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
Study: NCT03864406
Drug: Cobicistat
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each tablet of Tybost contains 150 mg of cobicistat.
Study: NCT03864406
Drug: Darunavir/Cobicistat
Normalized name: darunavir/cobicistat 800 mg-150 mg ORAL TABLET
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
Study: NCT03864406
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each tablet of Xarelto contains 10 mg of rivaroxaban.
Study: NCT03887702
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03887702
Drug: Tenofovir Alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03887702
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01705509
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
Study: NCT00578149
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00578149
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00578149
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03677973
Drug: AB680
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AB680 is a Cluster of Differentiation (CD)73 Inhibitor
Study: NCT04145531
Drug: IM JZP-458
Normalized name: JZP-386 free base
DrugBank: JZP-386 free base (DB17068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM JZP-458 will be administered in Part A, Cohorts 1 \& 2
Study: NCT04145531
Drug: IV JZP-458
Normalized name: JZP-386 free base
DrugBank: JZP-386 free base (DB17068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV JZP-458 will be administered in Part B
Study: NCT00575640
Drug: Hydralazine
Normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
Study: NCT01571518
Drug: early leukostim
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
Study: NCT00861562
Drug: Imescard water smartweed composed pills
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 01 pill at every 8 hours for 5 days.
Study: NCT00517088
Drug: IPAQ
Normalized name: Amipaque
DrugBank: Metrizamide (DB01578)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03583385
Drug: Glucophage XR (Test drug)
Normalized name: metformin Extended Release Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.
Study: NCT03583385
Drug: Glucophage XR (Comparator drug)
Normalized name: metformin Extended Release Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
Study: NCT03507387
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .
Study: NCT01504126
Drug: Propranolol Hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03507387
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive spinal anesthesia with bupivacaine.
Study: NCT03261427
Drug: Lyrica 150Mg Capsule
Normalized name: Lyrica 150mg Capsule
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg oral administered (BID)
Study: NCT04509219
Drug: Methylprednisolone Injection
Normalized name: methylprednisolone Injection
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone pulse therapy, 30mg/kg, with maximal dose of 1000mg/day, for continue 3 days.
Study: NCT03071042
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
Study: NCT03071042
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
Study: NCT03087448
Drug: Ceritinib
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~1. Ceritinib 300mg~2. Ceritinib 450mg~3. Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study
Study: NCT03087448
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~1. Trametinib 1.5mg~2. Trametinib 1.5mg~3. Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study
Study: NCT02721043
Drug: Poly-ICLC
Normalized name: Poly-ICLC
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
Study: NCT02721043
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
Study: NCT04494191
Drug: Flibanserin 100Mg Tab
Normalized name: FLIBANSERIN 100MG TAB
DrugBank: Flibanserin (DB04908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet contains 100 mg Flibanserin
Study: NCT04494191
Drug: Flibanserin 100 MG [Addyi]
Normalized name: flibanserin 100 MG [Addyi]
DrugBank: Flibanserin (DB04908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet contains 100 mg Flibanserin
Study: NCT00106769
Drug: VRC-WNVDNA017-00-VP
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00011999
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00011999
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00351052
Drug: Pimecrolimus
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecroliums cream 1 % bid.
Study: NCT01023815
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Study: NCT01023815
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
Study: NCT01023815
Drug: Prednison (continuous steroids)
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous steroids
Study: NCT00423917
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02835794
Drug: Omacetaxine
Normalized name: omacetaxine
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
Study: NCT02835794
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
Study: NCT02835794
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
Study: NCT00857714
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1500 mg lapatinib for 14-21 days
Study: NCT03085797
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
Study: NCT03085797
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations \[50 g/actuation\] in each nostril once daily).
Study: NCT01359085
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
Study: NCT04470076
Drug: Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ① Eligible patients with non-squamous cell lung cancer will receive pemetrexed 500mg/m2, IV on day 1 and cisplatin 75mg/m2 or carboplatin area under curve (AUC) =5, on day 1 of a 3-week schedule for 3 cycles.~② Eligible patients with squamous cell lung cancer will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC =5 on day 1 of a 3-week schedule for 3 cycles .~③Patient will take afatinib at dosage of 30mg per day 48 hours after chemotherapy and will stop 24 hours before next cycle of chemotherapy.